$DOCS

Doximity, Inc.

Doximity operates a professional platform for U.S. physicians and other medical professionals. The platform offers networking, profiles, search, career tools, a personalized medical newsfeed, and AI-powered clinical and workflow products. These include Ask, for clinical answers and administrative content; Scribe, for clinical documentation; Dialer, for telehealth; and tools for secure messaging, fax, prescribing, and on-call scheduling. The platform is free for U.S. medical professionals to join and use. Doximity makes money primarily by selling subscription-based Marketing, Hiring, and Workflow Solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare organizations. Marketing Solutions deliver sponsored content and related programs; Hiring Solutions provide recruiting tools and include Curative Talent, which charges health systems hourly or placement fees for staffing. Workflow Solutions include enterprise products for hospitals and health systems. Doximity is headquartered in San Francisco, California.

1
0
0
—
$441K
Wampler Kira Scherer
100%
See all $DOCS insider activity →
Low

DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems

Doximity (DOCS) expanded its AI tools to NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine, including Doximity Ask and Scribe. DOCS stock rose 0.4% post-announcement but is down 24.7% year-to-date. The collaboration aims to integrate AI into clinical workflows, potentially boosting DOCS's growth prospects. DOCS has a market cap of $5.95 billion.

Doximity (DOCS) Rolls Out DoseCheck After Near Zero Drug Dosing Errors

Doximity (DOCS) launched DoseCheck, an AI tool that reduces drug dosing errors by over 99%, according to the company. The feature is integrated into Doximity Ask and is free for users. The launch emphasizes AI safety and reliability, though monetization remains uncertain. Investors may watch for DoseCheck's impact on contract wins and renewals.

DOCS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning DOCS (Doximity, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent DOCS coverage spans financial news and earnings.

In the last 30 days, DOCS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($441K). The most active reporter was Wampler Kira Scherer with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving DOCS

  • The partnership may boost adoption of Doximity's AI tools, supporting modest share upside.

    zacks.com · Nov 16, 2026

  • Barclays kept Doximity at Equal-Weight, raising its price target to $30 from $27. This implies a 7.5% downside from the Nov 10 close of $32.42. Recent analyst price targets for Doximity range from $32 to $41.

    tradingview.com · Nov 11, 2026

  • The new safety feature may improve Doximity's value proposition to health systems and could support future revenue growth from AI-driven contracts.

    finance.yahoo.com · Nov 10, 2026

  • Freedom Capital Markets kept Doximity at a Hold rating, raising its price target to $32 from $27, citing an 18.5% increase. The new target suggests a 2.6% downside from the Nov 9 close of $32.87. Recent analyst price targets for Doximity range from $33 to $41.

    tradingview.com · Nov 10, 2026

  • Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

    finance.yahoo.com · Nov 10, 2026

AlphAI scores every news story that mentions DOCS with an AI model for sentiment and relevance, and aggregates insider trades from Doximity, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DOCS

Score

DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems

Doximity (DOCS) expanded its AI tools to NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine, including Doximity Ask and Scribe. DOCS stock rose 0.4% post-announcement but is down 24.7% year-to-date. The collaboration aims to integrate AI into clinical workflows, potentially boosting DOCS's growth prospects. DOCS has a market cap of $5.95 billion.

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

Related tickers